ReviewThe Lancet. Infectious diseases2018
Advancing the public health applications of Chlamydia trachomatis serology.
Review in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Pooled it
- Effect of neurogenic acupoint cupping on high sensitive C-reactive protein and pain perception in female chronic pelvic pain: A randomized controlled trial.Journal of musculoskeletal & neuronal interactions · 2021Trial
- Global temporal trends and projections for the incidence of chlamydial infection among women of childbearing age over the next decade.Medicine · 2026Article
- CRISPRi and beyond: studying essential gene function in the obligate intracellular bacteriumJournal of bacteriology · 2026Review
- Article
- Interactions of Mycoplasma genitalium (Mg) and human papillomavirus (HPV) infections among couples.BMC infectious diseases · 2025Article
- A single-tube RAA-CRISPR-Cas12a diagnostic platform for rapid detection of Chlamydia trachomatis.Journal of biological engineering · 2025Article
- UnveilingiScience · 2025Article
- Maternal-fetal transfer and longitudinal trends of antibodies to Chlamydia trachomatis and Mycoplasma genitalium in early childhood.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Current Progress and Future Perspective of Chlamydia trachomatis Infection: A Rising Threat to Women Health.Current microbiology · 2025Review
- Cross-sectional study on the seroprevalence, reinfection, and associated factors of Chlamydia trachomatis among female sex workers in Guangdong Province, China.BMC infectious diseases · 2025Article
- Timely Diagnosis of PID: Leveraging Ultrasound for Effective Management.Health science reports · 2025Article
- Risk factors associated with IgG seropersistence toEpidemiology and infection · 2025Article
- Prevalence and risk factors for Chlamydia trachomatis seropositivity and seropersistence among women: A prospective cohort study.PloS one · 2025Article
- Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.Vaccines · 2024Review
- The Emergence Potential ofArchives of Razi Institute · 2024Review
- Target Product Profile for a Machine Learning-Automated Retinal Imaging Analysis Software for Use in English Diabetic Eye Screening: Protocol for a Mixed Methods Study.JMIR research protocols · 2024Article
- Trends inSexually transmitted infections · 2024Article
- The serodiagnositic value ofFrontiers in public health · 2024Article
- Autophagy: the misty lands ofFrontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 6 countries.
Funding
Abstract
Genital Chlamydia trachomatis infection is the most commonly diagnosed sexually transmitted infection. Trachoma is caused by ocular infection with C trachomatis and is the leading infectious cause of blindness worldwide. New serological assays for C trachomatis could facilitate improved understanding of C trachomatis epidemiology and prevention. C trachomatis serology offers a means of investigating the incidence of chlamydia infection and might be developed as a biomarker of scarring sequelae, such as pelvic inflammatory disease. Therefore, serological assays have potential as epidemiological tools to quantify unmet need, inform service planning, evaluate interventions including screening and treatment, and to assess new vaccine candidates. However, questions about the performance characteristics and interpretation of C trachomatis serological assays remain, which must be addressed to advance development within this field. In this Personal View, we explore the available information about C trachomatis serology and propose several priority actions. These actions involve development of target product profiles to guide assay selection and assessment across multiple applications and populations, establishment of a serum bank to facilitate assay development and evaluation, and development of technical and statistical methods for assay evaluation and analysis of serological findings. The field of C trachomatis serology will benefit from collaboration across the public health community to align technological developments with their potential applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.